CA2744326A1 - Tcl1 as a transcriptional regulator - Google Patents

Tcl1 as a transcriptional regulator Download PDF

Info

Publication number
CA2744326A1
CA2744326A1 CA2744326A CA2744326A CA2744326A1 CA 2744326 A1 CA2744326 A1 CA 2744326A1 CA 2744326 A CA2744326 A CA 2744326A CA 2744326 A CA2744326 A CA 2744326A CA 2744326 A1 CA2744326 A1 CA 2744326A1
Authority
CA
Canada
Prior art keywords
tcl1
cells
activator protein
tcll
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2744326A
Other languages
English (en)
French (fr)
Inventor
Carlo M. Croce
Yuri Pekarsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CA2744326A1 publication Critical patent/CA2744326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2744326A 2008-11-21 2009-11-19 Tcl1 as a transcriptional regulator Abandoned CA2744326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11678608P 2008-11-21 2008-11-21
US61/116,786 2008-11-21
PCT/US2009/065072 WO2010059779A1 (en) 2008-11-21 2009-11-19 Tcl1 AS A TRANSCRIPTIONAL REGULATOR

Publications (1)

Publication Number Publication Date
CA2744326A1 true CA2744326A1 (en) 2010-05-27

Family

ID=42198493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2744326A Abandoned CA2744326A1 (en) 2008-11-21 2009-11-19 Tcl1 as a transcriptional regulator

Country Status (7)

Country Link
US (1) US20110311555A1 (enExample)
EP (1) EP2352524A1 (enExample)
JP (1) JP2012509886A (enExample)
CN (1) CN102271706A (enExample)
AU (1) AU2009316584A1 (enExample)
CA (1) CA2744326A1 (enExample)
WO (1) WO2010059779A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103820562B (zh) 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP2009507918A (ja) 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
EP2041317A4 (en) 2006-07-13 2009-10-14 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
EP2061907B1 (en) 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
ES2537349T3 (es) 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
EP2307028B1 (en) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US20010026796A1 (en) * 2000-03-14 2001-10-04 Croce Carlo M. TCL1 enhances Akt kinase activity and mediates its nuclear translocation
GB0128898D0 (en) * 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
CN1653059A (zh) * 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物

Also Published As

Publication number Publication date
WO2010059779A1 (en) 2010-05-27
AU2009316584A1 (en) 2010-05-27
US20110311555A1 (en) 2011-12-22
EP2352524A1 (en) 2011-08-10
CN102271706A (zh) 2011-12-07
JP2012509886A (ja) 2012-04-26

Similar Documents

Publication Publication Date Title
US20110311555A1 (en) Tc11 as a Transcriptional Regulator
Siegel et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
Yang et al. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation
Weijts et al. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1
CA2273821C (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
Chin et al. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma
Meng et al. Imbalanced Rab3D versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren's Syndrome
US20060234271A1 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
Weinstein et al. The oncogene heregulin induces apoptosis in breast epithelial cells and tumors
Li et al. NONO interacts with nuclear PKM2 and directs histone H3 phosphorylation to promote triple-negative breast cancer metastasis
Yeh et al. Isolation and properties of Gas8, a growth arrest-specific gene regulated during male gametogenesis to produce a protein associated with the sperm motility apparatus
JP2005040137A (ja) Ｊｎｋを標的化することによりプログラム細胞死またはアポトーシスをブロックする新規な因子の同定
US20060094013A1 (en) Salt-inducible kinases 2 and use thereof
US7906294B2 (en) Prognosis and treatment of breast cancer
US8722637B2 (en) Methods and compositions of IG20 and DENN-SV splice variants
US20020160002A1 (en) Tumor suppressor gene
JP2002503466A (ja) 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質
EP2021471B1 (en) Screening method
EP4168123B1 (en) Biomarker based patient selection for proteasome inhibitor treatment
Zhang et al. Phosphorylation dependent mitochondrial translocation of Nr4a3 provokes cardiomyocyte death
US7910704B2 (en) Human p53 splice variant displaying differential transcriptional activity
US20040009921A1 (en) Methods and compositions for the treatment of cancer
US20100113557A1 (en) Method for prevention of tumor
Ittmann Role of GGAP/PIKE-A in prostate cancer progression
Thompson Roles for protein kinase C and protein phosphatase 1 in nuclear lamina dynamics and cell cycle progression

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140807